- Home
- BPOP vs CYTK Comparison
BPOP vs CYTK Comparison
Compare BPOP & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | CYTK |
|---|---|---|
| Founded | 1893 | 1997 |
| Country | United States | United States |
| Employees | 9406 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | BPOP | CYTK |
|---|---|---|
| Price | $130.92 | $59.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $148.60 | $87.56 |
| AVG Volume (30 Days) | 489.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $11.33 | $9.79 |
| Revenue Next Year | $6.02 | $302.66 |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $78.23 | $29.31 |
| 52 Week High | $149.31 | $70.98 |
Technical Indicators
Market Signals| Indicator | BPOP | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 40.30 |
| Support Level | $122.73 | $59.25 |
| Resistance Level | $149.23 | $65.93 |
| Average True Range (ATR) | 4.44 | 2.65 |
| MACD | -1.61 | -0.32 |
| Stochastic Oscillator | 24.89 | 3.98 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.